Nektar Therapeutics reports results for the quarter ended December 31 - Earnings Summary

• Nektar Therapeutics NKTR.OQ reported quarterly adjusted earnings of 3 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -22 cents. The mean expectation of nine analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -21 cents to -10 cents per share.

• Revenue rose 22.1% to $29.18 million from a year ago; analysts expected $29.86 million.

• Nektar Therapeutics's reported EPS for the quarter was 3 cents​.

• The company reported quarterly net income of $7.26 million.

• Nektar Therapeutics shares had fallen by 11.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "hold."

Wall Street's median 12-month price target for Nektar Therapeutics is $4.00

This summary was machine generated from LSEG data March 12 at 09:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)